Efficacy and Safety of Lanthanum Carbonate and Sevelamer Hydrochloride in Patients Receiving Haemodialysis for End Stage Renal Disease
Status and phase
Completed
Phase 3
Conditions
Kidney Failure, Chronic
Treatments
Drug: Lanthanum carbonate
Study type
Interventional
Funder types
Industry
Identifiers
Details and patient eligibility
About
The purpose of this study is to assess phosphate reduction and control in patients with End Stage Renal Disease treated with either lanthanum carbonate or sevelamer hydrochloride
Sex
All
Ages
18+ years old
Volunteers
No Healthy Volunteers
Inclusion criteria
- Patients receiving haemodialysis for ESRD
- Patients must have received haemodialysis for chronic renal failure three times per week for at least the previous 2 months
Exclusion criteria
- Pregnant or lactating women
- Patients with clinically significant uncontrolled concurrent illness, a life-threatening malignancy or current multiple myeloma
- Patients who are HIV+
- Patients with any significant bowel obstruction, active inflammatory bowel disease, GI motility disorders, or a history of major GI surgery within the last 6 months
Trial design
Primary purpose
Treatment
Allocation
Randomized
Interventional model
Parallel Assignment
Masking
None (Open label)
Trial contacts and locations
0
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal
© Copyright 2024 Veeva Systems